Suchergebnisse - "EC 3.2.2.6"

PubPharm (3.283)

61

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab : case series

enthalten in: Hematology (Amsterdam, Netherlands) | 2022

von Djebbari, F. | Poynton, M. | Sangha, G. | +6

62

Downregulation of Sirt6 by CD38 promotes cell senescence and aging

enthalten in: Aging | 2022

von Zhou, H. | Liu, S. | Zhang, N. | +4

63

Persistent CD38 Expression on CD8 + T Lymphocytes Contributes to Altered Mitochondrial Function and Chronic Inflammation in People With HIV, Despite ART

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2022

von Mathur, P. | Kottilil, S. | Pallikkuth, S. | +2

64

Anti CD38 monoclonal antibodies for multiple myeloma treatment

enthalten in: Human vaccines & immunotherapeutics | 2022

von Gozzetti, A. | Ciofini, S. | Simoncelli, M. | +4

65

Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals

enthalten in: European journal of haematology | 2022

von Elizabeth, S. | Aidan, K. | David, O. | +16

66

Anti-CD38 monoclonal antibody interference with blood compatibility testing : Differentiating isatuximab and daratumumab via functional epitope mapping

enthalten in: Transfusion | 2022

von Chami, B. | Okuda, M. | Moayeri, M. | +15

67

CD38 as a multifaceted immunotherapeutic target in CLL

enthalten in: Leukemia & lymphoma | 2022

von Paulus, A. | Malavasi, F. | Chanan-Khan, A.

68

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma : differential mechanisms of action and recent clinical trial outcomes

enthalten in: Annals of hematology | 2022

von Leleu, X. | Martin, T. | Weisel, K. | +13

69

Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells

enthalten in: Cancer genomics & proteomics | 2022

von Saeed, M. | Boulos, J. | Mücklich, S. | +4

70

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies

enthalten in: Biomolecules | 2022

von Mustafa, N. | Azaman, M. | Ng, G. | +1